These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7803872)

  • 1. Stability and activity of intravenous immunoglobulin with neonatal dextrose and total parenteral nutrient solutions.
    Lindsay CA; Dang K; Adams JM; Ou CN; Baker CJ
    Ann Pharmacother; 1994 Sep; 28(9):1014-7. PubMed ID: 7803872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models.
    Givner LB
    Pediatrics; 1990 Dec; 86(6):955-62. PubMed ID: 2123536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation.
    Macias JM; Martin WJ; Lloyd CW
    Am J Hosp Pharm; 1985 May; 42(5):1087-94. PubMed ID: 3923832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin therapy of neonatal group B streptococcal infections: an overview.
    Fischer GW
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S13-6. PubMed ID: 3041355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced killing of group B streptococci in vitro by penicillin and opsonophagocytosis with intravenous immunoglobulin.
    Miller PS; Schauf V; Salo RJ
    J Infect Dis; 1990 Jun; 161(6):1225-30. PubMed ID: 2111840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directed immune globulin for the prevention or treatment of neonatal group B streptococcal infections: a review.
    Fischer GW; Weisman LE; Hemming VG
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S92-7. PubMed ID: 1728993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates.
    Weisman LE; Anthony BF; Hemming VG; Fischer GW
    J Pediatr; 1993 Jun; 122(6):929-37. PubMed ID: 8501574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compatibility of 5-fluorouracil and total parenteral nutrition solutions.
    Hardin TC; Clibon U; Page CP; Cruz AB
    JPEN J Parenter Enteral Nutr; 1982; 6(2):163-5. PubMed ID: 6808179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium and phosphate solubility in neonatal parenteral nutrient solutions containing TrophAmine.
    Fitzgerald KA; MacKay MW
    Am J Hosp Pharm; 1986 Jan; 43(1):88-93. PubMed ID: 3082196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of imipenem and cilastatin sodium in total parenteral nutrient solution.
    Zaccardelli DS; Krcmarik CS; Wolk R; Khalidi N
    JPEN J Parenter Enteral Nutr; 1990; 14(3):306-9. PubMed ID: 2112647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes.
    Fischer JH; Cwik MJ; Luer MS; Sibley CB; Deyo KL
    Ann Pharmacother; 1997 May; 31(5):553-9. PubMed ID: 9161647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of penicillins in total parenteral nutrient solution.
    Perry M; Khalidi N; Sanders CA
    Am J Hosp Pharm; 1987 Jul; 44(7):1625-8. PubMed ID: 3115097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual compatibility of 30 additives with a parenteral nutrient solution.
    Athanikar N; Boyer B; Deamer R; Harbison H; Henry RS; Jurgens R; Mett C; Sturgeon R; VanLeuven M; Welco A
    Am J Hosp Pharm; 1979 Apr; 36(4):511-3. PubMed ID: 107797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.
    Bolli R; Woodtli K; Bärtschi M; Höfferer L; Lerch P
    Biologicals; 2010 Jan; 38(1):150-7. PubMed ID: 19931468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional activity of class-specific antibodies to type III, group B streptococcus.
    Campbell JR; Baker CJ; Metzger TG; Edwards MS
    Pediatr Res; 1988 Jan; 23(1):31-4. PubMed ID: 3277150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High intravenous doses of human immune globulin suppress neonatal group B streptococcal immunity in rats.
    Weisman LE; Lorenzetti PM
    J Pediatr; 1989 Sep; 115(3):445-50. PubMed ID: 2671331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lorazepam stability in parenteral solutions for continuous intravenous administration.
    Hoey LL; Vance-Bryan K; Clarens DM; Wright DH; Konstantinides FN; Guay DR
    Ann Pharmacother; 1996 Apr; 30(4):343-6. PubMed ID: 8729885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous gamma globulin as adjunct therapy for severe group B streptococcal disease in the newborn.
    Friedman CA; Wender DF; Temple DM; Rawson JE
    Am J Perinatol; 1990 Jan; 7(1):1-4. PubMed ID: 2104748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of antibacterial and antitoxic activity of normal human immunoglobulin for intravenous use (IVIG)].
    Bucholc B; Banach W; Wysokińska T; Cieślik A; Chodorowska M
    Med Dosw Mikrobiol; 1996; 48(1-2):87-94. PubMed ID: 8926773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demonstration of opsonic and protective activity of human cord sera against type III group B streptococcus that are independent of type-specific antibody.
    Kim KS; Wass CA; Hong JK; Concepcion NF; Anthony BF
    Pediatr Res; 1988 Nov; 24(5):628-32. PubMed ID: 3060825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.